EXCELS, a post-marketing safety study of omalizumab (anti-IgE therapy), reported higher arterial thromboembolic events compared with non-users, whereas we found no significant association between omalizumab and myocardial infarction (possibly due to lower event rates, reducing statistical power), and a lower risk of stroke.13 This evidence concerns the gene IGHE and stroke disorder.